Related Experiment Video
Updated: Sep 19, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
DUSP14 attenuates airway inflammation and mucus hypersecretion in allergic asthma by regulating TAK1 activity
Rui Kong1, Jun Bai2, Qing Yao3
1Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China.
Abstract:
Allergic asthma is characterized by persistent chronic airway inflammation, leading to mucus hypersecretion and airway hyperresponsiveness. Dual-specificity phosphatase 14 (DUSP14), a member of the DUSP family, is a key regulator in various biological processes. However, the function of DUSP14 in allergic asthma remains to be elucidated. In this study, we aim to explore the function and mechanism of DUSP14 in asthma-related airway inflammation. In an ovalbumin (OVA) asthma mouse model, DUSP14 was found to be significantly diminished. DUSP14 overexpression relieved airway inflammation and attenuated airway mucus production. In vitro, overexpression of DUSP14 attenuated IL-13-induced cellular inflammation and mucus hypersecretion in bronchial epithelial cells (BEAS-2B). Afterwards, we used the co-immunoprecipitation assay to confirm that DUSP14 interacted with TAK1. DUSP14 overexpression restrained the activation of TAK1 and NF-κB signaling pathway in vitro and in vivo. Taken together, our findings clearly showed that DUSP14 could alleviate airway inflammation by inhibiting TAK1 activity and NF-κB signaling pathway, positioning the DUSP14-TAK1-NF-κB regulatory axis as a potential therapeutic target for allergic asthma.
Insights
Dual-specificity phosphatase 14 (DUSP14) alleviates allergic asthma by inhibiting the TAK1 and NF-κB pathway. This study reveals DUSP14 as a potential therapeutic target for reducing airway inflammation and mucus production in asthma.
Area of Science:
- Immunology
- Molecular Biology
- Respiratory Medicine
Background:
- Allergic asthma involves chronic airway inflammation, mucus hypersecretion, and hyperresponsiveness.
- Dual-specificity phosphatase 14 (DUSP14) regulates biological processes, but its role in asthma is unclear.
Purpose of the Study:
- To investigate the function and mechanism of DUSP14 in asthma-related airway inflammation.
- To explore DUSP14 as a potential therapeutic target for allergic asthma.
Main Methods:
- Ovalbumin (OVA)-induced asthma mouse model.
- In vitro studies using bronchial epithelial cells (BEAS-2B).
- Co-immunoprecipitation assay to identify protein interactions.
Main Results:
- DUSP14 levels were diminished in an OVA-induced asthma model.
- DUSP14 overexpression reduced airway inflammation and mucus production in vivo and in vitro.
- DUSP14 interacted with TAK1, inhibiting TAK1 and NF-κB signaling pathway activation.
Conclusions:
- DUSP14 alleviates allergic asthma by inhibiting the TAK1-NF-κB signaling pathway.
- The DUSP14-TAK1-NF-κB axis represents a promising therapeutic target for allergic asthma.
More Related Videos
07:52Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
Published on: July 23, 2012
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...